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ABSTRACT 
The present review describes the various indications of biliary 
stent placement in patients with biliary malignancies. It deals in 
depth with biliary accesses and their effectiveness, as well as with 
the use of different stents according to lesion type and expected 
patient survival. For liver hilum lesions, which are somewhat more 
complex, the usefulness of and need for unilateral or bilateral drain-
age is assessed, as it is the most appropriate method. All in all, this 
is an up-to-date literature review that may help clinicians in their 
daily decision-making, as well as to improve and optimize patient 
outcomes. 
Key words: Biliary tract cancer. Endoscopic retrograde chol-
angiopancreatography. Stents. Biliary tract surgical procedures. 
Palliative therapy.
INTRODUCTION
The etiology of malignant biliary stenosis varies accord-
ing to localization. Among liver hilum malignancies 
primary cholangiocarcinoma is the most common one, 
whereas pancreatic adenocarcinoma predominates in the 
distal bile duct (1) (Table I). Jaundice reflects an advanced 
stage of disease and is a marker of poor prognosis with 
scarce curative potential. In this setting, the key goal for 
stent placement is palliative in nature, but the procedure is 
increasingly indicated as a preoperative measure for sur-
gery with curative intent, or to achieve biliary patency in 
patients undergoing cancer therapy who will subsequently 
be reassessed and screened for surgery. Biliary stents play 
a key role for symptom relief and improved quality of life, 
but have failed to demonstrate higher survival rates (2).
Before the endoscopic procedure for biliary stent place-
ment we must assess a number of factors besides the neo-
plasm itself: patient clinical status, life expectancy, and 
stent indication, also considering cost-effectiveness. 
MATERIAL AND METHODS
Biliary drainage approach
Several strategies may be used to access the bile duct: 
endoscopic, percutaneous (interventionist radiology) or 
surgical. The endoscopic option is most useful and is con-
sidered as the primary option for biliary drainage (3).
The first description of biliary drainage for tumor-re-
lated obstructive jaundice using endoscopic retrograde 
cholangiopancreatography (ERCP) was performed by 
Soehendra in 1979. Spear and Cotton, in their papers pub-
lished in The Lancet journal in 1987 and 1994, respective-
ly, showed a greater effectiveness and lower complication 
rate for endoscopic versus percutaneous drainage. Com-
pared to surgical drainage, the endoscopic approach could 
not maintain patency with equal efficacy, but complication 
rate was lower. No significant differences in mortality were 
seen between biliary approaches (3-6).
Biliary drainage using interventionist radiology is usu-
ally a second option after a previously failed endoscopic 
attempt in standard clinical practice, or a complementary 
(rendezvous) strategy. Speer et al. demonstrated a high-
er success rate for the endoscopic versus percutaneous 
approach (81% vs. 61%; p = 0.017), with lower mortality 
at 30 days of follow-up in the endoscopic drainage group 
(15% vs. 33%; p = 0.016). The mortality associated with 
the percutaneous procedure arose from puncture-related 
complications, including bleeding, liver laceration and bile 
leakage (3,5).
Regarding lesions at the liver hilum ERCP becomes 
more complex, as more than just one stent is often required 
in a difficult-to-access area with restricted maneuverability 
(3). Bismuth-Corlette’s type-III (lesions reaching the con-
fluence of hepatic ducts and a primary branch) and type-IV 
(lesions reaching the confluence of hepatic ducts and both 
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primary branches) hepatic hilar neoplastic lesions (Fig. 1) 
are the most common ones, with rates of up to 60-70% or 
even higher, and most difficult to manage endoscopically. 
Some authors recommend the percutaneous approach for 
these lesions, particularly in less experienced centers or 
cases with challenging endoscopic access (7).
Of late, echoendoscopy-guided biliary drainage is being 
used as second option. While other approaches exist, bil-
iary drainage is mainly performed transgastrically via 
the left intrahepatic bile duct. This is an extremely useful 
method for patients with anatomic changes, such as those 
having undergone gastrectomy or duodenopancreatectomy. 
Another form of echoendoscopy-guided drainage is ren-
dezvous in combination with ERCP when access through 
the papilla of Vater has failed. These drain approaches are 
highly complex and should be attempted at third-level 
hospitals with highly trained endoscopists in ERCP and 
endoscopic ultrasounds (7-9).
Plastic versus metallic stents
The material a biliary stent is made of conditions its 
applicability, effectiveness and potential limitations. The 
primary characteristics differentiating plastic from metallic 
stents are summarized in table II (10-12).
Different classic studies have shown that metallic stents 
are superior in terms of permeability (13), symptom-free 
survival, shorter hospital stay and lower cost (14), both for 
distal and hepatic hilar lesions (15,16).
A meta-analysis was recently performed comparing 
the use of plastic and metallic biliary stents in patients 
with irresectable malignant biliary obstruction (2). All 
these studies were controlled clinical trials. A total of 24 
studies were included, 13 of them in patients with distal 
biliary malignancy, and 6 in patients with hepatic hilum 
neoplasms. Distal biliary malignancies included patients 
receiving both coated and partially coated metallic stents, 
but most (eight) studies involved uncoated stents. For 
hilar lesions all metallic stents were of the uncoated vari-
ety, and a high percentage of studies (5/6) included more 
patients with complex (Bismuth III or IV) lesions in the 
metallic versus plastic stent group. Final results showed 
that, when compared to plastic stents, metallic stents are 
less prone to occlusion (RR: 0.27; 95% CI: 0.13-0.60), 
although no significant differences in mortality at 30 days 
were observed between both groups (RR: 0.74); 95% CI: 
0.47-0.17) regarding all types of biliary stenosis. Overall, 
metallic stents are more effective and have fewer com-
plications regardless of lesion type. In the subgroup with 
distal biliary malignant stenosis successful insertion (RR: 
1.15; 95% CI: 0.56-2.37) and acute cholangitis (RR: 0.52; 
95% CI: 0.25-1.09) rates were no different between both 
stents. Possibly, in this anatomic location the benefits of 
greater adaptability and flexibility provided by metallic 
stents are not so obvious, given the favorable anatomy of 
the distal bile duct (2). 
From all the above we may conclude that metallic 
stents are the treatment of choice for malignant biliary 
obstruction. Their successful placement rate is similar to 
that of plastic stents but they also last longer, have fewer 
complications, reduce hospital admissions and mean stay, 
decrease the number of endoscopic procedures, and dimin-
ish overall costs (1,2,10,17,18).
Of all the variables discussed by prior studies only life 
expectancy was shown to be related to the use of metallic 
stents in terms of cost-effectiveness. Using a metallic stent 
for a patient with a life expectancy below 3 months was 
deemed as less cost-effective by virtually all studies. How-
ever, a recently reported clinical trial in 219 patients stud-
ied through 5 years in 18 Dutch and Belgian hospitals may 
Table I. Etiology of malignant biliary stenosis by site (modified from reference 1) 
Choledochal malignant stenosis Hilar/Intrahepatic malignant stenosis
Pancreatic head adenocarcinoma Hilar or intrahepatic cholangiocarcinoma
Cholangiocarcinoma Extrinsic compression by hilar adenopathies or liver metastasis
Gallbladder adenocarcinoma
Ampulloma
Extrinsic compression by gastric carcinoma, breast carcinoma or 
lymphoma
Neuroendocrine tumor
Fig. 1. Bismuth-Corlette classification. Type I: The lesion is near the hilum 
but does not invade it. Type II: The lesion invades the liver hilum but does 
not penetrate any branches. Type III: The lesion invades the liver hilum and 
involves the right (IIIa) or left (IIIb) branch. Type IV: The lesion invades the 
hilum and both (right and left) branches (modified from reference 21). 
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change this approach. This prospective, randomized study 
included patients with irresectable malignant stenosis of 
the extra-hepatic bile duct who received a plastic, uncoated 
metallic or partly coated metallic stent for jaundice pallia-
tion. Follow-up lasted for about 1 year. Fifty-two percent 
of patients had metastatic disease at diagnosis, and mean 
survival was 109 days. Endoscopy materials, staff, and 
hospital stay costs were analyzed per patient. For patients 
with a life expectancy equal or inferior to 3 months no 
statistically significant differences were seen in cost-ef-
fectiveness between plastic and metallic stents (€6,555 vs. 
€5,719, p = 0.4), as was also the case for subjects with 
metastasis at diagnosis (€6,593 vs. €6,179, p = 0.69). The 
authors concluded that metallic stents should be routinely 
used for all patients (2,10,17-19).
Coated metallic versus uncoated metallic stents
Uncoated metallic stents adhere to bile duct walls and, 
since neoplasms naturally tend to grow into the stent 
through the mesh, bile drain becomes obstructed and stents 
cannot be withdrawn. This type of metallic stents is the 
only one to be used for hilar lesions. However, these stents 
represent just an option among the other types for lesions 
in the distal bile duct (1,2,11,12,17).
Coated metallic stents do not adhere to biliary walls, 
hence the virtual space extant between the external coat 
material and the bile duct wall may become a real space 
over time because of bile sludge deposition and an epithe-
lial response to stent friction, mainly at stent ends. This 
allows potential stent withdrawal as well as stent migration 
after placement. They should not be used for hilar lesions 
since they may occlude collateral or intrahepatic branches, 
and trigger acute cholangitis. Furthermore, at the distal 
level cholecystitis and acute pancreatitis events have been 
described that may limit their use (1,2,17).
Amongst coated metallic stents we may distinguish 
fully coated stents, where the external coating includes 
the whole surface to both ends, and partly coated stents, 
where the mesh directly contacts the bile duct wall on their 
proximal and distal 5 mm-long ends. Partly coated stent 
design has been constantly revised to improve migration 
rates using “anti-migration” systems involving the grad-
ual tapering of the uncoated ends and a reduction in axial 
force, which provides a lower tendency to migrate inside 
the bile duct (20).
Saleem et al. used a meta-analysis to compare the effi-
cacy of coated versus uncoated metallic stents for the pal-
liative management of malignant distal biliary stenosis. 
The meta-analysis included 5 randomized clinical trials 
(2 clinical trials used fully coated metallic stents and 3 used 
partly coated metallic stents) for a total of 781 patients. 
The most common etiology was pancreatic adenocarci-
noma (69% of cases). Mean follow-up was 7 months, and 
2 studies used the percutaneous approach for stent place-
ment. Only 2 studies were included in the patient survival 
analysis. Patients receiving coated stents survived longer 
(51.18 days) than patients treated with uncoated stents 
(95% CI: 15.22-87.14; p = 0.01), a finding not shown 
by prior studies. Patency was superior for coated versus 
uncoated stents, with a mean difference of 60.56 days 
(95% CI: 25.96-95.17; p = 0.00). Coated stent dysfunction 
causes included choledochal epithelial reaction followed 
by cell overgrowth, bile sludge, and migration; uncoated 
stent dysfunction causes included tumor ingrowths through 
the mesh. In both cases findings were similar to those seen 
in other studies. Finally, the authors found no significant 
differences in acute cholecystitis (RR: 1.27; 95% CI: 0.41-
3.92; p = 0.67) or acute pancreatitis (RR: 1.27; 95% CI: 
0.25-6.39; p = 0.77) rates between both groups, which was 
seemingly inconsistent with the preconceived notion on 
this subject. Lastly, the sub-analysis comparing the use 
of fully versus partly coated stents found no statistically 
significant differences in any of the study endpoints (21).
Two years later, 2 meta-analyses were reported that com-
pared coated versus uncoated metallic stents with similar 
results (22,23). Yang et al. performed the research to com-
pare both stents using 11 studies (8 randomized controlled 
clinical trials, 3 prospective cohort studies) for a total of 
Table II. Differential characteristics between plastic and metallic stents (modified from reference 9)









–  Teflon (obsolete)
–  Polyurethane
–  Polyethylene
7,0-11,5 + + 3 months Any site –  Bile sludge
–  Bacterial 
overgrowth
–  Epithelial 
hyperplasia
The addition of 
an antibiotic or 
ursodeoxycholic 




–  AStainless steel
–  Nitinol (nickel-
titanium alloy)
–  Platinol (platinum 
core coated in 
nitinol) 







No material has 
proven superior 
to others
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684 patients with coated stents and 692 with uncoated stents 
for the treatment of malignant GI tract obstructions. No sig-
nificant differences were found between coated and uncoat-
ed stents in terms of biliary permeability (HR 0.73; 95% CI: 
0.41-1.32) or patient survival (HR 0.99; 95% CI: 0.77-1.28). 
This meta-analysis assessed exactly the same studies as the 
one by Saleem et al., but also included all the studies with 
available data regarding the analysis endpoints even if they 
did not involve all participants, and differences between 
coated and uncoated stents were not significant here (22).
In our setting a prospective, multicenter, non-random-
ized study was performed involving 32 Spanish hospitals 
to evaluate the efficacy and safety of partly coated metal-
lic stents for the management of extrahepatic irresect-
able malignant biliary stenosis. Enrollment included 199 
patients and mean follow-up was 18 months. The primary 
cause of biliary obstruction was pancreatic cancer (122 
patients), and 84.6% of patients had in situ gallbladder. 
In all, 74% of stents remained patent at 6 months, and 
only one procedure was needed to relieve jaundice in most 
subjects. As regards results, no patient had tumor growth 
through the mesh, stents migrated in 5% of patients (fewer 
than in prior studies: 4.9-13%), and only carrying a previ-
ous stent was related to higher migration rates in the mul-
tivariate analysis (OR 4.5; 95% CI: 1.1-17.8; p = 0.006). 
Epithelial overgrowth causing stent obstruction was seen 
in 5.5% of participants (much fewer than in prior studies). 
Acute cholecystitis developed in 2% of subjects, with other 
studies having reported proportions of up to 10%. Mor-
tality was 2%, similar to other studies. This paper demy-
stifies some complications that may raise doubts on the 
usefulness of metallic coated stents in clinical practice, 
and demonstrates their high effectiveness and safety (24).
Regarding the use of an anti-migration system in part-
ly coated metallic stents, these stents were compared to 
uncoated ones fitted with the same anti-migration feature. 
In a prospective, randomized study of 120 patients with 
irresectable pancreatic adenocarcinoma in 22 third-level 
sites no differences were found in mean patient survival 
between both groups (mean: 285 and 223 days, respective-
ly; p = 0.68). However, in the partially coated stent group 
stent patency was significantly higher (mean: 187 vs. 132 
days, respectively; p = 0.043). In no patient was migra-
tion found to be the cause of stent dysfunction, regardless 
of stent type (20). Recent studies also advocate for this 
anti-migration system in order to minimize stent dysfunc-
tion rates secondary to metallic stent mobility (1,25). 
To sum it all up, table III lists the advantages and dis-
advantages of both coated and uncoated metallic stents.
Preoperative biliary drainage
Surgery is the treatment of choice for potentially curable 
malignant biliary lesions. Surgery usually involves a com-
plex procedure with high morbidity and mortality. It has 
been suggested that hyperbilirubinemia in these patients 
may facilitate the development of sepsis, endotoxemia, 
and intravascular coagulation, which in turn would trigger 
hypercatabolism and malnutrition, thus increasing post-
operative complication rates and casting a gloom over an 
already poor prognosis (3). The usefulness of biliary drain-
age prior to resection surgery has been hence suggested. 
Preoperative drainage. Preliminary studies
Siddiqui et al., in a 5-year-long retrospective study, 
assessed 241 patients with resectable pancreatic cancer 
or scheduled for neo-adjuvant therapy, and showed that 
metallic stents were safe and effective for preoperative 
biliary drainage. Mean time between stent placement and 
surgery to relieve hyperbilirubinemia and provide patients 
with an optimal nutritional status was 4 weeks (3,26). With 
a retrospective design and lacking a control group, Singal 
et al. demonstrated that placing a metallic stent added no 
technical difficulties during surgery, and was a safe and 
effective measure in the setting of resectable or potential-
ly resectable neoplastic lesions following cancer therapy 
(3,27). Other similarly designed studies have shown that 
using a metallic stent leads to lower re-obstruction rates 
as compared to plastic stents, both in hilar (0% vs. 41%, 
Grunhagen et al., 2013) and distal (0% vs. 39%, Decker et 
al., 2011) lesions (3,28,29).


















Grey colors indicate features typical for each subtype. The “Both” category shows characteristics regarding which no significant differences were found by the relevant studies.
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Preoperative drainage. Randomized studies
In 2010, a multicenter study in the Netherlands attempt-
ed to gain a deeper insight into this subject (30). This 
research team carried out a prospective study in patients 
with distal biliary obstruction of neoplastic origin, eligible 
for surgery (90% pancreatic head neoplasms), with total 
bilirubin below 15 mg/dL, and with a computed tomogra-
phy (CT) scan revealing no metastasis or local invasion. 
Subjects were randomized into two groups: curative intent 
surgery within 7 days with no previous biliary drainage or 
ERCP for biliary drain placement using a plastic stent, fol-
lowed by surgery after 4-6 weeks. The rate of severe com-
plications requiring extended hospital stay or subsequent 
readmission, or leading to patient demise at 4 month’s 
follow-up was 39% in the early surgery group and 74% in 
the endoscopic drain group (RR 0.54; 95% CI 0.41-0.71; 
p < 0.001 in the early surgery arm). No difference in mor-
tality was found between groups. The main limitations of 
this study included a disproportionate rate of post-ERCP 
complications, mainly due to increased acute cholangitis 
(26%) among patients receiving preoperative drainage, and 
the fact that plastic rather than metallic stents were used 
(the superiority of self-expandable metallic stents in terms 
of effective drainage and lower complication rates is well 
known, and they add no difficulties to subsequent surgery) 
(17,30). Other studies have reported that preoperative bil-
iary drainage is more expensive (mean cost per patient 
of $15,616 vs. $11,914) and provides a scarce benefit in 
quality-adjusted life years (QALYs) (0.337 vs. 0.343) (17). 
To conclude, curative intent surgery without prior biliary 
drainage is indicated for patients with bilirubin below 15 
mg/dL and no acute cholangitis, provided the procedure 
may be accomplished within 7 days; otherwise, preopera-
tive biliary drainage is indicated (3) (Table IV). 
Neoadjuvant therapy and subsequent surgery
Pancreatic cancers are increasingly diagnosed as amena-
ble to neoadjuvant therapy, with potential curative intent 
surgery being considered according to tumor response. In 
these patients bile duct patency achievement is indicated 
before cancer therapy since breakthrough infection or high 
bilirubin levels would lead to treatment discontinuation 
and delayed surgery. A metallic stent is recommended to 
avert early obstruction during the lapse of time between 
cancer therapy onset and re-staging for subsequent surgery, 
bearing in mind that neoadjuvant therapy has a mean dura-
tion of 104 days in reported studies. Since plastic stents 
have a mean service life of about 90 days, stent obstruc-
tion would be fairly common before surgery (17,31,32). In 
this context metallic stents are safe, effective, and cost-ef-
fective, and do not require their removal before surgery 
provided there is a free proximal choledochal segment to 
allow a surgical anastomosis (32). 
Unilateral or bilateral drainage for malignant hilar 
lesions 
Malignant hilar lesions have a serpiginous, motley 
morphology, and obstruction usually develops at various 
points in the biliary tree, which requires a distinct man-
agement (2).
Hilar lesions may be divided up into 4 types of increas-
ing complexity (I-IV) according to the Bismuth-Corlette 
classification (33) (Fig. 1). Type-I lesions are usually 
solved with a unilateral drain, and type-IV lesions have a 
dismal prognosis, the predominantly obstructed lobe usual-
ly receiving a unilateral drain in clinical practice (2,34,35).
In order to compare unilateral versus bilateral drainage 
for non-resectable hilar lesions a meta-analysis was per-
formed including 634 patients in 7 studies, which found 
no significant differences in mortality at 30 days (OR 0.73; 
95% CI: 0.29-1.79) or stent obstruction rate regardless of 
stent type (metallic: OR: 1.09; 95% CI: 0.34-3.54; plastic: 
OR 1.86; 95% CI: 0.81-4.28), although studies were highly 
heterogeneous (I2
 = 62%). Nor were statistically significant 
differences found between unilateral and bilateral drainage 
in terms of therapy failure (OR: 0.63; 95% CI: 0.31-1.28) 
or acute cholangitis rate (OR 0.61; 95% CI: 0.27-1.38) (2).
In other studies unilateral drainage is less effective and 
obtains lower success rates when compared to bilateral 
drainage (Liberato et al., success rate of 11.9% for unilater-
al versus 31.4% for bilateral drainage) (36). Much has been 
discussed on this topic, but the key lies in proper planning 
before ERCP execution using imaging techniques (CT or 
magnetic resonance imaging [MRI]), with 3D images, to 
guide decisions and help come up with an “action plan” 
to facilitate subsequent therapy. Studies where bilateral 
drainage is more effective usually involve prior imaging 
(primarily CT or MRI scans) to guide the procedure, and 
patients selected using more objective criteria. More recent 
studies focus on whether one or two –even three– stents 
should be placed rather than on whether drainage should 
be unilateral or bilateral to drain over 50% of the hepatic 
volume. This is based on a study whose authors assessed 
which factors are predictive for drain effectiveness in 
patients with malignant hilar lesions (Bismuth II-IV). A 
total of 107 patients in 2 Parisian centers were retrospec-
tively included. ERCP was guided by prior CT and/or MRI 
Table IV. Preoperative biliary drainage indications. 




Cholestasis with sustained high bilirubin
URGENT: acute cholangitis
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scans, which divided the liver in 3 main sectors (anterior 
right, posterior right, and left, according to the main bile 
duct branches running parallel to the portal vein), taking 
into account the total hepatic volume drained by each sec-
tor. In their results, the authors observed that drain effec-
tiveness, measured as a reduction in baseline bilirubin lev-
els to at least half at 30 days during follow-up, was better 
when > 50% of hepatic volume was drained (OR: 4.5; 95% 
CI 1.07-6.46; p = 0.001), particularly for Bismuth III hilar 
stenosis, and that in patients reaching said drainage volume 
survival was higher (119 vs. 59 days, p = 0.005). Most 
often, draining > 50% of hepatic volume involved placing 
a drain in at least 2 of the 3 sectors. It was also shown that 
the draining of an atrophic lobe, with drainage for less 
than 30% of hepatic volume, represented no advantage and 
increased acute cholangitis rates following the procedure 
(OR 3.04; 95% CI: 1.24-7.48; p = 0.01) (2,34). 
From all this, in biliary drainage skipping atrophic sec-
tors and using the number of stents necessary for draining 
at least 50% of total hepatic volume is most appropriate, 
particularly for Bismuth II and III lesions. Metallic stents 
should be used except for patients with survival below 
3-6 months, and first-line access should be endoscopic, 
with the percutaneous option being considered for complex 
hilar lesions (Bismuth III-IV) (2,10,17,34,35). 
Bilateral drainage primarily with metallic stents may be 
approached with two distinct techniques: stent-in-stent or 
side-by-side. Only a few studies assess which method is 
more effective or has fewer complications. Overall, metallic 
stent success rates using both methods range from 73.3% to 
100%, according to studies. Stent placement using the side-
by-side technique is technically more complex and challeng-
ing, but stent patency rates over time are higher (35). 
CONCLUSIONS
–  The best way to gain access to the bile duct is the 
endoscopic approach for all cases except complex 
hilar lesions (usually Bismuth III-IV), where a per-
cutaneous route may be considered as the first option 
in less experienced sites.
–  Metallic stents are better than plastic stents for any 
biliary lesions and in all settings, their price being the 
limiting factor. They are considered to be not cost-ef-
fective in patients with estimated survival below 
3 months, but recent papers raise doubts on this. 
–  The different metallic stent models available hardly 
differ in terms of patency duration and patient surviv-
al, their potential complications being their limiting 
factors. Uncoated stents should be used for the intra-
hepatic bile duct, whereas partly coated stents fitted 
with an anti-migration system are most promising in 
the extrahepatic bile duct.
–  Preoperative biliary drainage should not be per-
formed routinely and is to be avoided in the absence 
of an urgent indication when total bilirubin is lower 
than 15 mg/dL and elective surgery may be scheduled 
within 7 days. Subsequent surgery should not condi-
tion stent type. When needed, metallic stents should 
be used. For patients scheduled to receive neo-adju-
vant therapy, a metallic stent should always be used 
to ensure biliary permeability.
–  The endoscopic drainage of hilar lesions should be 
carried out according to Bismuth level and under the 
guidance of a prior imaging technique, preferably 
MRI. Number of stents and their location should be 
selected to provide a bile drainage > 50% of hepatic 
volume. Stents should not be placed in atrophic liver 
sectors. There is very little evidence regarding the 
best technique for bilateral drainage. 
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